Patents by Inventor Elena Burova
Elena Burova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250092139Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand 1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: February 15, 2024Publication date: March 20, 2025Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Publication number: 20240397919Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: August 13, 2024Publication date: December 5, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Publication number: 20240389563Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: August 15, 2024Publication date: November 28, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20240316361Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: ApplicationFiled: April 24, 2024Publication date: September 26, 2024Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 12096754Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: July 29, 2021Date of Patent: September 24, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Patent number: 12089575Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: December 3, 2020Date of Patent: September 17, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20240298619Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: May 12, 2023Publication date: September 12, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
-
Patent number: 12024570Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: October 14, 2020Date of Patent: July 2, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
-
Publication number: 20240166740Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: May 15, 2023Publication date: May 23, 2024Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON
-
Publication number: 20230235089Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.Type: ApplicationFiled: November 23, 2022Publication date: July 27, 2023Inventors: Ella Ioffe, Elena Burova
-
Patent number: 11692032Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: June 6, 2019Date of Patent: July 4, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
-
Patent number: 11684050Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: November 4, 2019Date of Patent: June 27, 2023Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20210380702Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: August 11, 2021Publication date: December 9, 2021Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Publication number: 20210360908Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: July 29, 2021Publication date: November 25, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Patent number: 11117970Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: February 26, 2018Date of Patent: September 14, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 11102961Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: April 18, 2019Date of Patent: August 31, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Publication number: 20210105983Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: December 3, 2020Publication date: April 15, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20210040232Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: October 14, 2020Publication date: February 11, 2021Inventors: Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON, William OLSON
-
Patent number: 10881086Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: January 30, 2018Date of Patent: January 5, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Patent number: 10844137Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: July 26, 2018Date of Patent: November 24, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson